vorinostat has been researched along with Acute Promyelocytic Leukemia in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Licht, JD | 1 |
| He, LZ | 1 |
| Tolentino, T | 1 |
| Grayson, P | 1 |
| Zhong, S | 1 |
| Warrell, RP | 1 |
| Rifkind, RA | 1 |
| Marks, PA | 1 |
| Richon, VM | 1 |
| Pandolfi, PP | 1 |
| Amin, HM | 1 |
| Saeed, S | 1 |
| Alkan, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for vorinostat and Acute Promyelocytic Leukemia
| Article | Year |
|---|---|
Targeting aberrant transcriptional repression in leukemia: a therapeutic reality?
Topics: Cell Adhesion; Enzyme Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Leukemia, Promyelo | 2001 |
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Cell Cycle; Cell D | 2001 |
Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17).
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Apoptosis; Butyrates; Carr | 2001 |